Comparison of adverse drug reactions with donepezil versus memantine: Analysis of the French pharmacovigilance database

Therapie

Volumn 65, Issue 3, 2010, Pages 255-259

  Babai, Samy ^a   Auriche, Pascal ^b   Le Louët, Hervé ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b AFSSAPS   (France)

Author keywords

Adverse drug reactions; Alzheimer disease; Donepezil; Memantine; Pharmacovigilance

Indexed keywords

DONEPEZIL; MEMANTINE; INDAN DERIVATIVE; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE;

AGE DISTRIBUTION; ALZHEIMER DISEASE; ARTICLE; BLOOD DISEASE; BRADYCARDIA; CONVULSION; DATA BASE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FRANCE; GASTROINTESTINAL DISEASE; HEART DISEASE; HEPATOBILIARY DISEASE; HUMAN; MENTAL DISEASE; METABOLIC DISORDER; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SKIN DISEASE; VASCULAR DISEASE; WEAKNESS; AGED; COMPARATIVE STUDY; FACTUAL DATABASE; FEMALE; MALE; MIDDLE AGED; POSTMARKETING SURVEILLANCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; DATABASES, FACTUAL; FEMALE; FRANCE; HUMANS; INDANS; MALE; MEMANTINE; MIDDLE AGED; NOOTROPIC AGENTS; PIPERIDINES; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 77955754711     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie/2010008     Document Type: Article

References (22)

1. Ferri CP, Prince M, Brayne C, et al. Alzheimer's Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366 (9503): 2112-7
2. J Health Syst Pharm 2009; 66 (10): 899-907
3. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; (1): CD005593
4. Thompson S, Lanctôt KL, Herrmann N. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. Expert Opin Drug Saf 2004; 3 (5): 425-40
5. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. Memantine Study Group. JAMA 2004; 291 (3): 317-24
6. Hsiung GY, Feldman HH. Pharmacological treatment in moderate-to-severe Alzheimer's disease. Expert Opin Pharmacother 2008; 9 (15): 2575-82
7. Downey D. Pharmacologic management of Alzheimer disease. J Neurosci Nurs 2008; 40 (1): 55-9
8. Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 2009; 80: 600-7
9. Weycker D, Taneja C, Edelsberg J, et al. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil. Curr Med Res Opin 2007; 23 (5): 1187-97
10. Gallini A, Sommet A, Montastruc JL, et al. Does memantine induce bradycardia? A study in the French PharmacoVigilance Database. Pharmacoepidemiol Drug Saf 2008; 17 (9): 877-81
11. Clerici F, Vanacore N, Elia A, et al. Memantine in moderately-severe-to- severe Alzheimer's disease: a postmarketing surveillance study. Drugs Aging 2009; 26 (4): 321-32
12. Erkent U, Koytchev R. The use of truncated area under the curves in the bioequivalence evaluation of long half-life drugs. Studies with donepezil and memantine. Arzneimittelforschung 2008; 58 (5): 255-8
13. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008; 148 (5): 379-97
14. Pariente A, Helmer C, Merliere Y, et al. Prevalence of cholinesterase inhibitors in subjects with dementia in Europe. Pharmacoepidemiol Drug Saf 2008; 17 (7): 655-60
15. Tavassoli N, Sommet A, Lapeyre-Mestre M, et al. Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary). Drug Saf 2007; 30 (11): 1063-71
16. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356 (9237): 1255-9
17. Bégaud B, Evreux JC, Jouglard J, et al. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie 1985; 40 (2): 111-8
18. Periclou AP, Ventura D, Sherman T, et al. Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Ann Pharmacother 2004; 38 (9): 1389-94
19. Dantoine T, Auriacombe S, Sarazin M, et al. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. Int J Clin Pract 2006; 60 (1): 110-8
20. Riepe MW, Adler G, Ibach B, et al. Adding memantine to rivastigmine therapy in patients with mild-to-moderate Alzheimer's disease: results of a 12-Week, open-label pilot study. Prim Care Companion J Clin Psychiatry 2006; 8 (5): 258-63
21. Dolder C, Nelson M, McKinsey J. Memantine dosing in patients with dementia. Am J Geriatr Psychiatry 2009; 17 (2): 170-3
22. Lindquist M. Data quality management in pharmacovigilance. Drug Saf 2004; 27 (12): 857-70